Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

Brpf1 Inhibitors

Chemical inhibitors of Brpf1 are designed to disrupt the protein's role in epigenetic regulation by targeting its bromodomain or associated complexes. I-CBP112, PFI-3, OF-1, Olinone, and NI-57 are compounds that directly engage with the bromodomain of Brpf1. These inhibitors function by binding to the bromodomain, which is responsible for recognizing acetylated lysine residues on histone tails, a key interaction necessary for Brpf1 to exert its effects on chromatin remodeling and gene expression. As these inhibitors occupy the bromodomain's acetyl-lysine recognition site, Brpf1 is prevented from associating with chromatin, thus inhibiting its ability to contribute to the transcriptional machinery. SGC-CBP30 operates on a similar principle, competing with acetylated histones for binding to Brpf1's bromodomain, which results in functional inhibition of the protein's role in reading the chromatin state.

On the other hand, some inhibitors such as CPI-455 and GSK6853 do not directly inhibit the bromodomain but instead target associated complexes or domains that are vital for Brpf1's function. CPI-455 interacts with the KAT6A/B complex, which involves Brpf1, leading to reduced histone acetylation and consequently impairing Brpf1's regulatory role in gene expression. GSK6853 selectively inhibits the acetyl-lysine recognition domain of Brpf1, compromising its chromatin interaction capabilities. A-485 targets p300/CBP histone acetyltransferases that interact with Brpf1, thereby disrupting its recruitment of histone modifiers. BIX-01294, while primarily an inhibitor for other histone-modifying enzymes, can alter histone methylation patterns and indirectly affect Brpf1's chromatin interactions. Similarly, EPZ-5676's inhibition of the histone methyltransferase DOT1L alters the methylation of histone H3, a modification recognized by Brpf1, which can impact its chromatin recruitment. Lastly, MS-275 disrupts class I HDAC activity, leading to increased histone acetylation, which may interfere with the specific histone marks Brpf1 requires for its function in chromatin remodeling.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

9-[5-Deoxy-5-[[cis-3-[2-[6-(1,1-dimethylethyl)-1H-benzimidazol-2-yl]ethyl]cyclobutyl](1-methylethyl)amino]-β-D-ribofuranosyl]-9H-purin-6-amine

1380288-87-8sc-500607
50 mg
$13500.00
(0)

EPZ-5676 inhibits DOT1L, a histone methyltransferase that methylates lysine 79 of histone H3, a modification that Brpf1 can bind to. Inhibition of DOT1L can therefore disrupt Brpf1’s function by altering the chromatin landscape and impeding the recruitment of Brpf1 to its target sites.

MS-275

209783-80-2sc-279455
sc-279455A
sc-279455B
1 mg
5 mg
25 mg
$24.00
$90.00
$212.00
24
(2)

MS-275 is a class I HDAC inhibitor that increases acetylation of histones, which may interfere with Brpf1's normal binding to specific histone marks, thereby inhibiting Brpf1’s function in chromatin remodeling and gene regulation by altering the epigenetic landscape that Brpf1 acts upon.